减低剂量阿扎胞苷联合维奈克拉作为急性髓系白血病强化或低强度诱导后的维持治疗:单中心、单臂、2期试验
这项单中心、单臂、2期研究在德克萨斯大学MD安德森癌症中心纳入35例达到完全缓解或完全缓解伴血细胞计数未完全恢复、且不适合立即行异基因造血干细胞移植的急性髓系白血病成人患者,评估减低剂量阿扎胞苷联合维奈克拉维持治疗的疗效与安全性。全队列中位无复发生存期未达到(95%CI 20.2至不可计算),2年无复发生存率为65%(95%CI 50-85)。作者认为该方案是强化和低强度诱导后可行的维持策略。
要点
- 全队列中位无复发生存期未达到(95%CI 20.2至不可计算),2年无复发生存率65%(95%CI 50-85)。
- 队列1(强化诱导后)2年无复发生存率71%(95%CI 53-94),队列2(低强度诱导后)为52%(95%CI 27-100)。
- 最常见3-4级治疗中出现的不良事件为血小板减少(n=6)、肺部感染(n=4)、白细胞减少(n=4)和中性粒细胞减少(n=3),维持治疗期间无死亡。
核心结论
- 减低剂量阿扎胞苷联合维奈克拉是急性髓系白血病强化和低强度诱导后可行的维持策略。
研究设计与样本
- 单中心、单臂、2期研究,在美国德克萨斯大学MD安德森癌症中心进行。
- 纳入年龄≥18岁、WHO 2016标准诊断为急性髓系白血病、经强化或低强度诱导后达到完全缓解或完全缓解伴血细胞计数未完全恢复、且不适合立即行异基因造血干细胞移植的成人患者。
- 东部肿瘤协作组体能状态评分须≤3分。
- 患者接受阿扎胞苷50 mg/m2静脉或皮下给药5天联合维奈克拉400 mg口服7天或14天的维持治疗。
- 主要结局为无复发生存期;研究因入组缓慢提前关闭;所有患者均纳入疗效和安全性分析。
主要发现
- 全队列中位无复发生存期未达到(95%CI 20.2至不可计算),队列1未达到(95%CI 29.1至不可计算),队列2为30.3个月(95%CI 16.5至不可计算)。
- 全队列2年无复发生存率为65%(95%CI 50-85),队列1为71%(95%CI 53-94),队列2为52%(95%CI 27-100)。
- 最常见的3-4级治疗中出现的不良事件为血小板减少(n=6)、肺部感染(n=4)、白细胞减少(n=4)和中性粒细胞减少(n=3)。
- 维持治疗期间无死亡发生。
局限性
- 研究因入组缓慢提前关闭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute myeloid leukaemia have high rates of relapse, especially if they are unable to complete standard consolidation strategies or allogeneic haematopoietic stem-cell transplantation (HSCT). The phase 3 QUAZAR AML-001 study showed an overall survival benefit with oral azacitidine maintenance. The BCL2 inhibitor venetoclax is highly active in acute myeloid leukaemia and synergistic with azacitidine. We aimed to evaluate the efficacy and safety of low dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia. METHODS: We performed a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center in the USA. Eligible patients were adults (aged ≥18 years) with a WHO 2016 diagnosis of acute myeloid leukaemia in complete remission or complete remission with incomplete blood count recovery following intensive or low-intensity induction and not immediately eligible for HSCT. Eastern Cooperative Oncology Group performance status had to be 3 or less. Patients were assigned to maintenance therapy with azacitidine 50 mg/m2 intravenously or subcutaneously for 5 days and venetoclax 400 mg orally for 7 days or 14 days. The primary outcome was relapse-free survival. The study was closed early due to slow accrual. All patients were included in the efficacy and safety analyses. This trial is registered with ClinicalTrials.gov (NCT04062266). FINDINGS: Between Sept 26, 2019, and Oct 26, 2022, 35 patients were enrolled, of whom 25 (71%) were assigned to cohort 1 following intensive induction and ten (29%) to cohort 2 following low-intensity induction. Of 35 patients, 18 (51%) were male and 17 (49%) were female. The median age was 55 years (IQR 41-62). The median number of cycles given was 9 (IQR 2-22) and median follow-up time was 23·3 months (IQR 9·0-30·0). The median relapse-free survival was not reached (95% CI 20·2 to not calculable) in the full cohort, not reached (29·1 to not calculable) in cohort 1, and 30·3 months (16·5 to not calculable) in cohort 2. The 2-year relapse-free survival was 65% (95% CI 50-85) in the full cohort, 71% (53-94) in cohort 1, and 52% (27-100) in cohort 2. The most common grade 3-4 treatment-emergent adverse events were thrombocytopenia (n=6), lung infection (n=4), leukopenia (n=4), and neutropenia (n=3). No deaths occurred during maintenance therapy. INTERPRETATION: Low dose azacitidine plus venetoclax is a feasible maintenance strategy in acute myeloid leukaemia following intensive and low-intensity induction. FUNDING: University of Texas MD Anderson Cancer Center, MDS/AML Moon Shot, Genentech.
引用
- Bazinet A, Kantarjian H, Bataller A, et al. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024. PMID: 38548404. doi:10.1016/S2352-3026(24)00034-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。